| Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia. | |
| | |
MedLine Citation:
|
PMID: 9800809 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Cardiopulmonary bypass contributes to platelet loss and dysfunction by exposure to shear stresses, foreign surfaces, and hypothermia. This study tested the hypothesis that pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) accelerates recovery of the platelet population after hypothermic extracorporeal circulation (HEC). METHODS: In a blinded study, subcutaneous injections of drug or placebo were given to dogs daily for 3 days preoperatively (day 0, 1, and 2) with no drug on day 3. On day 4, the animal was prepared for arteriovenous HEC. After heparinization, HEC was initiated at 30 to 40 mL x kg(-1) x min(-1). Hypothermic extracorporeal circulation (25 degrees C) was continued for 90 minutes. RESULTS: Preoperative platelet count (x10(3) platelets/microL) did not differ from predrug count in placebo (256+/-27 versus 255+/-20) or PEG-rHuMGDF (271+/-30 versus 291+/-38). During 60 minutes of HEC, the platelet count decreased to approximately 10% of baseline in placebo (29+/-5) and PEG-rHuMGDF (46+/-8), and recovered to approximately 70% of baseline after rewarming (90 minutes of HEC: placebo, 185+/-17, versus PEG-rHuMGDF, 169+/-22). After HEC, platelet count was greater in PEG-rHuMGDF-treated animals (p < 0.05) without altering function (aggregation responses). Within the first 6 hours after HEC, platelet count in PEG-rHuMGDF-treated animals was rising and increased to 260+/-29 (p < 0.01), but was unchanged in placebo animals (186+/-21). Thereafter, platelet count in placebo animals declined to a nadir of 124+/-15 (72 hours after HEC), whereas platelet count in PEG-rHuMGDF animals approximated the preoperative value (>200) at all times. CONCLUSIONS: Appropriately timed presurgical administration of PEG-rHuMGDF counteracts post-HEC relative thrombocytopenia without increasing platelet population and enhancing aggregation preoperatively or during extracorporeal circulation. |
| | |
Authors:
|
M Nakamura; C F Toombs; I G Duarte; R S Ronson; L S Schmarkey; S L Katzmark; J Robinson; D L Dillehay; J Vinten-Johansen; R A Guyton |
Related Documents
:
|
16139569 - Evaluation of platelet parameters in healthy apheresis donors using the advia 120. 10074589 - Management of heparin-induced thrombocytopenia during continuous renal replacement ther... 931359 - Factor analysis of finger ridge-counts in blacks and whites. 22236469 - Synthesis and evaluation of platelet aggregation inhibitory activity of some 3-phenyl-p... 11553059 - Platelet count and parameters determined by the bayer advia 120 in reference subjects a... 7233509 - Donor platelet response and product quality assurance in plateletpheresis. 18842039 - Superconductivity induced by co-doping in quaternary fluoroarsenide cafeasf. 6726619 - Possible role of endothelium in the vasodilator response of rat thoracic aorta to plate... 1450179 - Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. flow ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Annals of thoracic surgery Volume: 66 ISSN: 0003-4975 ISO Abbreviation: Ann. Thorac. Surg. Publication Date: 1998 Oct |
Date Detail:
|
Created Date: 1998-12-02 Completed Date: 1998-12-02 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 15030100R Medline TA: Ann Thorac Surg Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1216-23 Citation Subset: AIM; IM |
Affiliation:
|
Department of Surgery, Carlyle Fraser Heart Center of Emory University, Atlanta, Georgia, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood Coagulation / drug effects Blood Platelets / drug effects Cardiopulmonary Bypass / adverse effects* Dogs Humans Hypothermia, Induced Injections, Subcutaneous Platelet Aggregation / drug effects Platelet Count / drug effects Polyethylene Glycols / administration & dosage, pharmacology* Preoperative Care Recombinant Proteins / administration & dosage, pharmacology Thrombocytopenia / etiology, prevention & control* Thrombopoietin / administration & dosage, pharmacology* Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Polyethylene Glycols; 0/Recombinant Proteins; 0/polyethylene glycol-recombinant human megakaryocyte growth and development factor; 9014-42-0/Thrombopoietin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Heparin preserves nitric oxide activity in coronary endothelium during ischemia-reperfusion injury.
Next Document: Morbidity, cost, and six-month outcome of minimally invasive direct coronary artery bypass grafting.